Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer

By sjmartinez • October 26, 2023

Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 Mar;165(3):828-839.e5. doi: 10.1016/j.jtcvs.2022.10.007. Epub 2022 Oct 8. PMID: 36369159; PMCID: PMC10288861.

Tags: Hematology/Oncology, immunotherapy, Lung cancer, neoadjuvant therapy, Publications

Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

Brady MR, Matulionis N, Christofk HR, Garon EB, Lisberg A, Shackelford DB, Momcilovic M. Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous[...]

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis

Liu W, Duan W, Xia S, Liu Y, Chu H, Liang K, Fang S, Lin M, Wei S, You X, Hu Q, Qi J, Wang[...]

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry

Daskou M, Zaiss AK, Jeyachandran AV, Takano KA, Kan RL, Paravastu R, Gerald E, Satheeshkumar N, Rios-Rodriguez J, Russell B, Brault AC, Bhaduri A, Garcia[...]